2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The biopharma industry saw the approval of 55 new products in 2025. This development occurred despite uncertainty and tumult at the FDA. The approvals suggest the industry was able to achieve successes amidst challenging conditions.